Novavax Expands Collaboration And License Agreement With Sanofi On Use Of Matrix-M Adjuvant
I'm PortAI, I can summarize articles.
Novavax, Inc. has expanded its collaboration and license agreement with Sanofi SA to include the use of its Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program. The amendment allows Sanofi to utilize Matrix-M through Phase 2 development, with potential negotiations for license rates if Phase 3 is reached. Novavax could receive up to $200 million for the first four products and up to $210 million in milestone payments for subsequent products, along with ongoing royalties.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments